Amith Chordia serves as the Vice President of the Oncology Business Unit and is part its senior leadership, bringing to the team twelve years of experience in oncology and immunology. Since joining SAI in January 2017, Mr. Chordia has been dedicated to SAI’s Oncology Business Unit and provides executive oversight and management of projects across solid tumors and hematological malignancies, with focus on NSCLC, GI cancers, and lymphomas. He primarily supports the competitive intelligence, clinical development, and commercial and new product planning functions for several biotech and big pharma clients. He regularly attends all major oncology conferences, including ASCO, ESMO, EHA, and ASH, and also routinely attends individual tumor-focused oncology conferences.

Prior to joining SAI, he was instrumental in the success of Renovo Neural, a Cleveland Clinic spinoff with strong commercial revenues and drug assets. His role involved overseeing all expansion and commercialization activities, working directly with the executive team. He also successfully built and led a sales team at Safeline Formulations Ltd., a generic drug manufacturer in India. Mr. Chordia received his MS in entrepreneurial biotechnology from Case Western Reserve University, Cleveland, Ohio.